Overview
For years, the story of GLP-1 medications like semaglutide (Wegovy) and tirzepatide (Zepbound) has been told in pounds lost. This month, cardiologists added a new chapter. In the span of about a week — at the American Heart Association's Scientific Sessions in Chicago and then at ObesityWeek 2026 in Washington — researchers presented data suggesting these drugs don't just shrink waistlines in people with obesity and heart failure. They may actually improve the heart's pressures, structure, and function, and in one randomized trial, more than half of treated patients went into heart failure remission. Here's what the new research found, where the evidence is strong and where it's still thin, and what it means if you're weighing GLP-1 treatment.

